Back to Search Start Over

Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study

Authors :
Kajetan von Eckardstein
Thomas Westermaier
Michael Richter
Andreas Wienke
Tobias Engelhorn
Cordula Matthies
Fred G. Barker
Christian Scheller
Maria Teresa Pedro
Johannes Zenk
Malte Kornhuber
Oliver Ganslandt
Veit Rohde
Gregor Antoniadis
Kristofer F. Ramina
Thomas Kretschmer
Barbara Bischoff
Joerg Steighardt
Christian Strauss
Alireza Gharabaghi
Marcos Tatagiba
Source :
Journal of Neurosurgery. 127:1376-1383
Publication Year :
2017
Publisher :
Journal of Neurosurgery Publishing Group (JNSPG), 2017.

Abstract

OBJECTIVEIn clinical routines, neuroprotective strategies in neurosurgical interventions are still missing. A pilot study (n = 30) and an analogously performed Phase III trial (n = 112) pointed to a beneficial effect of prophylactic nimodipine and hydroxyethyl starch (HES) in vestibular schwannoma (VS) surgery. Considering the small sample size, the data from both studies were pooled.METHODSThe patients in both investigator-initiated studies were assigned to 2 groups. The treatment group (n = 70) received parenteral nimodipine (1–2 mg/hour) and HES (hematocrit 30%–35%) from the day before surgery until the 7th postoperative day. The control group (n = 72) was not treated prophylactically. Facial and cochlear nerve functions were documented preoperatively, during the inpatient care, and 1 year after surgery.RESULTSPooled raw data were analyzed retrospectively. Intent-to-treat analysis revealed a significantly lower risk for hearing loss (Class D) 12 months after surgery in the treatment group compared with the control group (OR 0.46, 95% CI 0.22–0.97; p = 0.04). After exclusion of patients with preoperative Class D hearing, this effect was more pronounced (OR 0.38, 95% CI 0.17–0.83; p = 0.016). Logistic regression analysis adjusted for tumor size showed a 4 times lower risk for hearing loss in the treatment group compared with the control group (OR 0.25, 95% CI 0.09–0.63; p = 0.003). Facial nerve function was not significantly improved with treatment. Apart from dose-dependent hypotension (p < 0.001), the study medication was well tolerated.CONCLUSIONSProphylactic nimodipine is safe and may be recommended in VS surgery to preserve hearing. Prophylactic neuroprotective treatment in surgeries in which nerves are at risk seems to be a novel and promising concept.Clinical trial registration no.: DRKS 00000328 (https://drks-neu.uniklinik-freiburg.de/drks_web/)

Details

ISSN :
19330693 and 00223085
Volume :
127
Database :
OpenAIRE
Journal :
Journal of Neurosurgery
Accession number :
edsair.doi.dedup.....3c89463e0f44eee2cb0f44c1b0d17874
Full Text :
https://doi.org/10.3171/2016.8.jns16626